The Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. An assessment by the Australian and New Zealand Intensive Care Society

Anaesthesia and Intensive Care

Volumn 36, Issue 2, 2008, Pages 149-151

  Hicks, P ^a   Cooper, D J ^a   Webb, S ^a   Myburgh, J ^a   Seppelt, I ^a   Peake, S ^a   Joyce, C ^a   Stephens, D ^a   Turner, A ^a   French, C ^a   Hart, G ^a   Jenkins, I ^a   Burrell, A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; DROTRECOGIN; HYPERTENSIVE FACTOR; NORADRENALIN; STEROID;

BLOOD PRESSURE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DISEASE SEVERITY; EDITORIAL; EMERGENCY CARE; FLUID RESUSCITATION; GLYCEMIC CONTROL; HEART OUTPUT; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE; NEW ZEALAND; RESUSCITATION; SEPSIS; SEPTIC SHOCK; STEROID THERAPY;

EID: 41349121371     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0803600202     Document Type: Editorial

References (12)

1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34:17-60.
2. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327.
3. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377.
4. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367.
5. van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449-461
6. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125-139.
7. Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871.
8. Sprung CL, Annane D, Keh D. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124.
9. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
10. Eichacker PQ, Natanson C, Danner RL. Surviving sepsis - practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 2006; 355:1640-1642.
11. Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J et al. A comparison of epinephrine and norepinephrine on reversal of shock. Intensive Care Med 2007; 33: S197
12. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356:2139-2143